Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.

Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR.

J Immunother Cancer. 2014 Dec 16;2(1):46. doi: 10.1186/s40425-014-0046-9. eCollection 2014.

2.

Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.

Olin MR, Pluhar GE, Andersen BM, Shaver R, Waldron NN, Moertel CL.

Crit Rev Immunol. 2014;34(5):399-432. Review.

3.

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.

Waldron NN, Barsky SH, Dougherty PR, Vallera DA.

Target Oncol. 2014 Sep;9(3):239-49. doi: 10.1007/s11523-013-0290-9. Epub 2013 Jul 31.

4.

Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A, Vallera DA.

Gynecol Oncol. 2013 Sep;130(3):579-87. doi: 10.1016/j.ygyno.2013.05.027. Epub 2013 May 27.

5.

Immunotoxin targeting CD133(+) breast carcinoma cells.

Ohlfest JR, Zellmer DM, Panyam J, Swaminathan SK, Oh S, Waldron NN, Toma S, Vallera DA.

Drug Deliv Transl Res. 2013 Apr;3(2):195-204. doi: 10.1007/s13346-012-0066-2.

PMID:
25787984
6.

Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.

Waldron NN, Oh S, Vallera DA.

Oral Oncol. 2012 Dec;48(12):1202-7. doi: 10.1016/j.oraloncology.2012.06.002. Epub 2012 Jul 20.

7.

Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.

Waldron NN, Kaufman DS, Oh S, Inde Z, Hexum MK, Ohlfest JR, Vallera DA.

Mol Cancer Ther. 2011 Oct;10(10):1829-38. doi: 10.1158/1535-7163.MCT-11-0206. Epub 2011 Aug 23.

Supplemental Content

Loading ...
Support Center